The scale of the problem has led analysts to predict that the market for RSV vaccines could eventually be worth several billion dollars a year. In trials, GSK’s vaccine significantly reduced the ...

caused by RSV through day 150 in healthy pre-term and full-term infants compared to placebo. The company plans to file the data with global regulatory authorities, setting up a possible market ...

End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump administration.

AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to ...

In preclinical animal trials, third-party testing results showed that AIM Vaccine's mRNA RSV vaccine achieved significantly higher levels of specific IgG antibody titers, live-virus neutralizing ...